Investors Are Watching : CDK Global (NASDAQ:CDK), Alpha Natural Resources (NYSE:ANR), Ultragenyx Pharmaceutical (NASDAQ:RARE), Titan Machinery (NASDAQ:TITN), Golar LNG Partners (NASDAQ:GMLP)

CDK Global, Inc. (NASDAQ:CDK), the largest provider of integrated information technology and digital marketing and advertising solutions to the automotive industry, plans to expand its presence in downtown Detroit. The firm will lease additional space to provide advanced digital marketing insights and services for its clients in the automotive industry. The project will generate a total capital investment of nearly $3.6 million and add 100 … Continue reading Investors Are Watching : CDK Global (NASDAQ:CDK), Alpha Natural Resources (NYSE:ANR), Ultragenyx Pharmaceutical (NASDAQ:RARE), Titan Machinery (NASDAQ:TITN), Golar LNG Partners (NASDAQ:GMLP)

Kevin Long10/08

Stock Runners : Merck & Co. Inc. (NYSE:MRK), Trinity Industries Inc. (NYSE:TRN), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), WellCare Health Plans, Inc. (NYSE:WCG), LRAD

Bayer has completed the global acquisition of the consumer care business of the U.S. pharmaceuticals group Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, New Jersey. The transaction closed on October 1, 2014, following receipt of required antitrust approvals. “This acquisition is a milestone for Bayer and we intend to continue the expansion of our attractive over-the-counter business both through organic growth and bolt-on acquisitions,” explained … Continue reading Stock Runners : Merck & Co. Inc. (NYSE:MRK), Trinity Industries Inc. (NYSE:TRN), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), WellCare Health Plans, Inc. (NYSE:WCG), LRAD

John Bellich10/02

Investors Are Watching : Ultragenyx Pharmaceutical (NASDAQ:RARE), Bankrate, Inc. (NYSE:RATE), American Shared Hospital Services (NYSEMKT:AMS), Calamos Asset (NASDAQ:CLMS), Canadian National Railway (NYSE:CNI)

Ultragenyx Pharmaceutical (NASDAQ:RARE) SVP Thomas Richard Kassberg unloaded 20,000 shares of the stock on the open market in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $53.91, for a total transaction of $1,078,200.00. Following the sale, the senior vice president now directly owns 105,804 shares in the company, valued at approximately $5,703,894. The sale was disclosed in … Continue reading Investors Are Watching : Ultragenyx Pharmaceutical (NASDAQ:RARE), Bankrate, Inc. (NYSE:RATE), American Shared Hospital Services (NYSEMKT:AMS), Calamos Asset (NASDAQ:CLMS), Canadian National Railway (NYSE:CNI)

Chris Lewis09/15

Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on July 9 announced the pricing of its underwritten public offering of 2,017,349 shares of its common stock at a price to the public of $40.00 per share, before underwriting discounts. Ultragenyx is selling 1,311,277 shares of its common stock in this offering, and certain selling stockholders are selling 706,072 shares of common stock in this offering. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) … Continue reading Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Adam Keintzel07/1007/10

Biotech Volatile Stocks: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sorrento Therapeutics (NASDAQ:SRNE), Five Prime Therapeutics (NASDAQ:FPRX), Aratana Therapeutics (NASDAQ:PETX), Pain Therapeutics (NASDAQ:PTIE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc. (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, … Continue reading Biotech Volatile Stocks: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sorrento Therapeutics (NASDAQ:SRNE), Five Prime Therapeutics (NASDAQ:FPRX), Aratana Therapeutics (NASDAQ:PETX), Pain Therapeutics (NASDAQ:PTIE)

Jayne Crisman06/26

Biotech Bearish Stocks: Zalicus Inc (NASDAQ:ZLCS), Stemline Therapeutics Inc (NASDAQ:STML), Agenus Inc (NASDAQ:AGEN), Arrowhead Research Corp (NASDAQ:ARWR), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Zalicus Inc (NASDAQ:ZLCS) on June 18 announced that it has licensed its Sodium Channel Modulator program, including intellectual property and related pipeline assets, to AnaBios Corporation in exchange for clinical milestone payments and royalties on potential future sales. Under the terms of the agreement Zalicus will be eligible to receive up to $17.2 million in clinical and regulatory milestone payments and up to 12% of … Continue reading Biotech Bearish Stocks: Zalicus Inc (NASDAQ:ZLCS), Stemline Therapeutics Inc (NASDAQ:STML), Agenus Inc (NASDAQ:AGEN), Arrowhead Research Corp (NASDAQ:ARWR), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Kevin Long06/2006/20